GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (HKSE:03347) » Definitions » Research & Development

Hangzhou Tigermed Consulting Co (HKSE:03347) Research & Development : HK$252 Mil (TTM As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Hangzhou Tigermed Consulting Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Hangzhou Tigermed Consulting Co's Research & Development for the three months ended in Mar. 2025 was HK$63 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was HK$252 Mil.


Hangzhou Tigermed Consulting Co Research & Development Historical Data

The historical data trend for Hangzhou Tigermed Consulting Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Tigermed Consulting Co Research & Development Chart

Hangzhou Tigermed Consulting Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 185.70 259.38 262.00 286.08 254.52

Hangzhou Tigermed Consulting Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.42 65.44 52.20 70.77 63.34

Hangzhou Tigermed Consulting Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$252 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hangzhou Tigermed Consulting Co  (HKSE:03347) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Hangzhou Tigermed Consulting Co Research & Development Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Hangzhou Tigermed Consulting Co Business Description

Traded in Other Exchanges
Address
Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.
Executives
Sands Capital Management, Llc 2101 Beneficial owner
Sands Capital Management, Lp 2201 Interest of corporation controlled by you
Sands Family Trust, Llc 2201 Interest of corporation controlled by you
Sands Frank Melville Jr. 2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
F-j Sands Family I, Llc 2201 Interest of corporation controlled by you
2017 Eagle Holdings Llc 2201 Interest of corporation controlled by you
Citigroup Inc. 2201 Interest of corporation controlled by you
Ubs Group Ag 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co. 2502 Approved lending agent
Ninety One Plc/ Ninety One Ltd 2102 Investment manager
Ninety One Uk Limited 2102 Investment manager
Baillie Gifford & Co 2102 Investment manager

Hangzhou Tigermed Consulting Co Headlines

No Headlines